Reports September 2017

 

 

Pregabalin worker's guide

Pregabalin is a medication used for seizures, anxiety and neuropathic pain. It is also known by a brand name Lrica® and various street names. In recent years it’s use has become prolific across Northern Ireland is also seen in other parts of the UK among heroin users and the prison population. It is involved in ever more fatal overdoses in these groups/region | Injecting Advice, UK

Pubs quizzed: What publicans think about drug policy, public health and the changing trade (PDF)

There is significant common ground between public health bodies and publicans, and scope to develop policies approved of by both groups | IAS, UK

What Britain's ideal pub looks like

In a 1946, George Orwell detailed what he wanted from his ideal public house, the fictitious “Moon Under Water”. While some of Orwell’s preferences have not aged well (such as serving beer in strawberry-pink china mugs and being able to use the pub’s telephone), new YouGov Omnibus research shows that many aspects of Orwell’s ideal pub have stood the test of time | YouGov, UK

Research published into gang and drug related violence

Academics at the University of Suffolk have been looking into a rise in gang and drug related violence in the county | University of Suffolk, UK

Still no harm reduction? A critical review of the UK Government’s new Drug Strategy (PDF)

This briefing, endorsed by eight of the UK’s leading harm reduction and drug treatment organisations, looks at whether the focus on harm reduction has improved under the new Drug Strategy (2017), and discusses challenges in the funding environment which will have a disproportionate impact on harm reduction services | National AIDS Trust - secretariat to the English Harm Reduction Group, UK

A nation with ambition (PDF)

The government's programme for Scotland 2017/18. Includes an announcement regarding a overhaul of the current drug strategy | Scottish Government, UK

Mapping the Maze

Mapping the Maze is a new report aiming to map service provision specifically for women facing homelessness, substance misuse, poor mental health, offending and complex needs generally | Agenda, UK

Commissioning impact on drug treatment

This independent report by the ACMD investigates the impact of commissioning on drug treatment. It looks at: commissioning structures, contracting arrangements and the financial environment, the impact on recovery outcomes for individuals and communities | ACMD, UK

Annual Surveillance Report of Drug-Related Risks and Outcomes (PDF)

The purpose of this first annual surveillance report is to summarize the latest information available on the national level for various health outcomes, health behaviors, and prescribing patterns related to the drug problem in the United States | CDC, USA

Inquiry into the Drugs, Poisons and Controlled Substances Amendment (Pilot Medically Supervised Injecting Centre) Bill (PDF)

The Drugs, Poisons and Controlled Substances Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017 (the Bill) seeks to amend the Drugs, Poisons and Controlled Substances Act 1981 (the Principal Act), to provide for the licencing and operation of a medically supervised injecting centre (MSIC) for a trial period of 18 months | Parliament of Victoria, Australia

Guidance: Alcohol: applying All Our Health

Examples and interventions to help people live healthy lifestyles, make healthy choices and reduce health inequalities | PHE, UK

Deaths by drug poisoning where any opiates were mentioned on the death certificate, local authorities in England and Wales, 1993 to 2016

Deaths involving opiates by English and Welsh local authorities, deaths registered between 1993 and 2016 | ONS, UK

The Lammy Review (PDF)

An independent review into the treatment of, and outcomes for Black, Asian and Minority Ethnic individuals in the criminal justice system | Lammy Review, UK

CLeaR local tobacco control assessment

Supporting local public health organisations to undertake the CLeaR assessments to review and improve their tobacco control work | PHE, UK

NPS at CREW Anuual Report (PDF)

This document provides an update of the NPS scene and an overview of drug trends in Scotland, from 01 April 2016 to 31 March 2017 | Crew, UK

Guidance: Alcohol: applying All Our Health

Examples and interventions to help people live healthy lifestyles, make healthy choices and reduce health inequalities | PHE, UK

Charter for change (PDF)

The Drugs, Alcohol & Justice Cross-Party Parliamentary Group provides an interface for professional providers of drug and alcohol treatment with parliamentarians of all parties who share an interest in these issues. We seek to focus attention on addiction issues and advocate evidence-based policies, enabling treatment services to save and transform more lives | Drugs, Alcohol & Justice Cross-Party Parliamentary Group, UK

Multiple Needs: Time for political leadership

The government has stated its determination to tackle an escalating set of crises: homelessness, substance misuse, mental ill health and persistently high re-offending rates. Despite some progress, there is currently a fundamental flaw in the way we deal with these problems: we treat them as separate when they are connected. If this doesn’t change, things will only get worse – with appalling human and financial consequences | MEAM, UK

Models of delivery for stop smoking services. Options and evidence

This document supports directors of public health and local healthcare commissioners in rapidly appraising the evidence, to enable informed decisions on the provision of local stop smoking support | PHE, UK

EMCDDA–Europol Joint Report on a new psychoactive substance: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide (CUMYL-4CN-BINACA)

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3- carboxamide, commonly known as CUMYL-4CN-BINACA, through a joint assessment | EMCDDA, Portugal

EMCDDA–Europol Joint Report on a new psychoactive substance: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran-2-carboxamide (tetrahydrofuranylfentanyl; THF-F)

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran- 2-carboxamide, commonly known as tetrahydrofuranylfentanyl (THF-F), through a joint assessment | EMCDDA, Portugal

EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA)

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint assessment | EMCDDA, Portugal

EMCDDA–Europol Joint Report on a new psychoactive substance: N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyrylfentanyl; 4F-iBF)

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide, commonly known as 4-fluoroisobutyrylfentanyl (4F-iBF), through a joint assessment | EMCDDA, Portugal

EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA)

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint assessment | EMCDDA, Portugal

EMCDDA–Europol Joint Report on a new psychoactive substance: methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA; 5F-ADB)

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}- 3,3-dimethylbutanoate, commonly known as 5F-MDMB-PINACA, through a joint assessment | EMCDDA, Portugal

Public Health England marketing strategy: 2017 to 2020

This strategy sets out Public Health England's 3-year strategic framework | PHE, UK

Liverpool’s Drink Less Enjoy More Intervention Progress Monitoring Report (PDF)

[Updated September] UK nightlife environments are characterised by high levels of drunkenness and alcohol related health and social harms (Bellis & Hughes, 2011). Such high levels of intoxication in city centres across the UK belie the fact that the sale of alcohol to, or purchase of alcohol for intoxicated individuals has been illegal for over 400 years | PHI, UK

Psychoactive substances in secure mental health settings

This document reviews the impact of new psychoactive substances (NPS) in secure mental health settings, and makes recommendations for the management of NPS use in these settings | PHE, UK

Dealing with Synthetics: Time to Reframe the Narrative (PDF)

Beginning with an overview of the synthetics market, this Policy Report examines the possible sources of such inertia and critically explores the issues underlying what in many respects represents a key yet largely under discussed feature of the extant international drug control system. It is argued here that, considering its policy history and contemporary dynamics, it is now time to reframe the narrative surrounding the way the international community deals with synthetic drugs | GDPO, UK

Guidance: Alcohol, drugs and tobacco: commissioning support pack

Annually updated alcohol, drugs and tobacco commissioning support pack for local authorities | PHE, UK

Estimates of the Prevalence of Opiate Use and/or Crack Cocaine Use, 2014/15: Sweep 11 report (PDF)

This report presents the findings of Sweep 11 of the estimates of the prevalence of opiate and/or crack cocaine use (OCU) in England, covering 2014/15. These continue the long time series of OCU prevalence estimates, starting in 2004/05 and most recently reported for 2011/12 | CPH, UK

 

 

 

 

 

 

 

Home : Terms of use : Contact
Copyright DrugWise©2016